Literature DB >> 24385600

Efficacy of thyroid blockade on thyroid radioiodine uptake in 123I-mIBG imaging.

Nicholas C Friedman1, Aamna Hassan, Erin Grady, Dale T Matsuoka, Arnold F Jacobson.   

Abstract

UNLABELLED: Although iodinated radiopharmaceuticals usually contain a small quantity of unbound iodine, it is difficult to establish the degree to which thyroid activity on scintigraphic images reflects uptake of free radioiodine. The objective of the present study was to examine the effectiveness of thyroid blockade in subjects undergoing (123)I-meta-iodobenzylguanidine (mIBG) imaging and to estimate the relative contribution of bound and unbound radioiodine to imaging findings.
METHODS: All subjects were participants in prospective trials of (123)I-mIBG cardiac imaging in which pretreatment with thyroid blockade was optional unless locally required. In a pilot project, 15 subjects (6 blocked) had thyroid uptake measured at 4 h using a probe system. Fifteen-minute (early) and 4-h (late) anterior planar chest images that included the thyroid region were visually scored for thyroid uptake (scale of 0-4) in another group of 152 subjects (98 blocked). Quantitative analysis based on thyroid regions of interest was performed on anterior planar images from a further sample of 669 subjects (442 blocked). For all 3 investigations, quantitative comparisons of thyroid uptake were made between the blocked and nonblocked subjects.
RESULTS: There was no statistical difference between probe uptake of the 6 blocked and 9 nonblocked subjects. However, in the second series, mean visual score on the late images was significantly lower for blocked than nonblocked subjects (P < 0.001). In the region-of-interest analyses, net thyroid counts were significantly higher on the late images of nonblocked subjects (P < 0.0001), and compared with early images, 87% of subjects who received blockade showed decreased or unchanged counts whereas 75% of nonblocked subjects had increased net thyroid activity. In nonblocked subjects, an estimated 79% of thyroid counts on late images could be attributed to unbound (123)I.
CONCLUSION: On the basis of 3 different methods for assessing thyroid uptake of (123)I, use of thyroid blockade pretreatment in (123)I-mIBG imaging prevents increase of thyroid activity over time because of uptake of unbound (123)I. In most subjects, there is a low level of (123)I-mIBG thyroid activity that probably represents specific uptake in sympathetic nerve terminals.

Entities:  

Keywords:  123I; blockade; mIBG; thyroid

Mesh:

Substances:

Year:  2014        PMID: 24385600     DOI: 10.2967/jnumed.113.124826

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  9 in total

1.  Thyroid blockade in 123I-mIBG cardiac imaging: A common sense approach.

Authors:  Arnold F Jacobson
Journal:  J Nucl Cardiol       Date:  2015-05-14       Impact factor: 5.952

2.  Preclinical Pharmacokinetics and Dosimetry Studies of 124I/131I-CLR1404 for Treatment of Pediatric Solid Tumors in Murine Xenograft Models.

Authors:  Ian R Marsh; Joseph Grudzinski; Dana C Baiu; Abigail Besemer; Reinier Hernandez; Justin J Jeffery; Jamey P Weichert; Mario Otto; Bryan P Bednarz
Journal:  J Nucl Med       Date:  2019-03-29       Impact factor: 10.057

3.  ASNC imaging guidelines for SPECT nuclear cardiology procedures: Stress, protocols, and tracers.

Authors:  Milena J Henzlova; W Lane Duvall; Andrew J Einstein; Mark I Travin; Hein J Verberne
Journal:  J Nucl Cardiol       Date:  2016-06       Impact factor: 5.952

4.  1-23I-MIBG thyroid uptake: Implications for MIBG imaging of the heart.

Authors:  Raffaele Giubbini; Elisa Milan; Claudio Marcassa; Barbara Paghera; Federica Fracassi; Luca Camoni; Carlo Rodella; Francesco Bertagna; Federica Motta; Mattia Bertoli; Riccardo Campini
Journal:  J Nucl Cardiol       Date:  2015-05-13       Impact factor: 5.952

5.  European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma.

Authors:  David Taïeb; Rodney J Hicks; Elif Hindié; Benjamin A Guillet; Anca Avram; Pietro Ghedini; Henri J Timmers; Aaron T Scott; Saeed Elojeimy; Domenico Rubello; Irène J Virgolini; Stefano Fanti; Sona Balogova; Neeta Pandit-Taskar; Karel Pacak
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-06-29       Impact factor: 9.236

6.  Development of tumor-targeting aza-vesamicol derivatives with high affinity for sigma receptors for cancer theranostics.

Authors:  Kenji Mishiro; Mengfei Wang; Saki Hirata; Takeshi Fuchigami; Kazuhiro Shiba; Seigo Kinuya; Kazuma Ogawa
Journal:  RSC Med Chem       Date:  2022-06-30

Review 7.  Cardiac 123I-mIBG Imaging in Heart Failure.

Authors:  Derk O Verschure; Kenichi Nakajima; Hein J Verberne
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-25

8.  Thyroid function after diagnostic 123I-metaiodobenzylguanidine in children with neuroblastic tumors.

Authors:  Sarah C Clement; Godelieve A M Tytgat; A S Paul van Trotsenburg; Leontien C M Kremer; Hanneke M van Santen
Journal:  Ann Nucl Med       Date:  2022-05-02       Impact factor: 2.258

9.  Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system.

Authors:  Alexander Bolaender; Danuta Zatorska; Huazhong He; Suhasini Joshi; Sahil Sharma; Chander S Digwal; Hardik J Patel; Weilin Sun; Brandon S Imber; Stefan O Ochiana; Maulik R Patel; Liza Shrestha; Smit K Shah; Shuo Wang; Rashad Karimov; Hui Tao; Pallav D Patel; Ananda Rodilla Martin; Pengrong Yan; Palak Panchal; Justina Almodovar; Adriana Corben; Andreas Rimner; Stephen D Ginsberg; Serge Lyashchenko; Eva Burnazi; Anson Ku; Teja Kalidindi; Sang Gyu Lee; Milan Grkovski; Bradley J Beattie; Pat Zanzonico; Jason S Lewis; Steve Larson; Anna Rodina; Nagavarakishore Pillarsetty; Viviane Tabar; Mark P Dunphy; Tony Taldone; Fumiko Shimizu; Gabriela Chiosis
Journal:  Nat Commun       Date:  2021-08-03       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.